-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, MAIA Biotechnology Secures $2.44M In Private Placement, Aiming To Fund Key Phase 2 THIO-101 Cancer Trial

Benzinga·10/29/2024 07:43:20
Listen to the news

The gross proceeds from the offering are expected to be approximately $2.44 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund manufacturing of THIO to be used in the Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC) and as working capital.